TCT
TEVA icon

TIAA CREF Trust’s Teva Pharmaceuticals TEVA Stock Holding History

TIAA CREF Trust’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,371
Closed -$477K – 363
2016
Q3 		$477K Buy
10,371
+190
+2% +$9.91K ﹤0.01% 330
2016
Q2 		$511K Buy
+10,181
New +$542K ﹤0.01% 315
2016
Q1 		– Sell
-11,082
Closed -$727K – 343
2015
Q4 		$727K Sell
11,082
-952
-8% -$58.8K 0.01% 269
2015
Q3 		$679K Buy
12,034
+1,330
+12% +$86.2K 0.01% 268
2015
Q2 		$633K Sell
10,704
-7,482
-41% -$462K 0.01% 267
2015
Q1 		$1.13M Sell
18,186
-2,671
-13% -$155K 0.01% 226
2014
Q4 		$1.2M Buy
20,857
+5,322
+34% +$297K 0.01% 217
2014
Q3 		$835K Sell
15,535
-3,517
-18% -$186K 0.01% 242
2014
Q2 		$999K Sell
19,052
-4,533
-19% -$232K 0.01% 226
2014
Q1 		$1.25M Buy
23,585
+701
+3% +$32.4K 0.02% 198
2013
Q4 		$917K Buy
22,884
+586
+3% +$23.1K 0.02% 225
2013
Q3 		$842K Sell
22,298
-2,443
-10% -$95.3K 0.02% 206
2013
Q2 		$970K Buy
+24,741
New +$963K 0.02% 189

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

TIAA CREF Trust's TEVA Position: Q4 2016 in Review

TIAA CREF Trust sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 10,371 shares — an estimated $477K sold.

TIAA CREF Trust first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $1.25M in Q1 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • TIAA CREF Trust reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • TIAA CREF Trust sold 10,371 Teva Pharmaceuticals shares in Q4 2016, an estimated $477K.
  • TIAA CREF Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • TIAA CREF Trust's Teva Pharmaceuticals position peaked at $1.25M in Q1 2014.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on TIAA CREF Trust's 13F filing for Q4 2016, filed 30 Jan 2017.